Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
NCT06464926 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this research study is to determine if the Enterra® Therapy System can decrease nausea and vomiting symptoms and improve the quality of life for patients with chronic nausea, with or without vomiting, that have normal gastric emptying.
Interventions
- DEVICE Enterra Therapy System
Study Locations (17)
Other
- UZ Leuven — Leuven
- Hôpital Louis-Mourier — Colombes
- Hôpital Edouard Herriot - CHU de Lyon — Lyon
- CHU de Bordeaux — Pessac
- CHU de Rouen — Rouen
- Sahlgrenska Universitetssjukhuset — Gothenburg
California
- Hoag Hospital — Newport Beach
- Sutter Health — San Francisco
Arizona
- Mayo Clinic Arizona — Scottsdale
Florida
- University of South Florida — Tampa
Illinois
- Endeavor Health — Evanston
Indiana
- Indiana University Health — Indianapolis
Kentucky
- University of Louisville — Louisville
New Jersey
- Hackensack Meridian — Neptune City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2025-06-23 |
| Est. Completion | 2030-06 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06464926
The ClinicalTrials.gov registry entry for NCT06464926 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enterra Medical, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Nausea appearing as the primary indexed condition, and to 1 intervention — of which Enterra Therapy System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06464926 reports 17 study locations spanning 11 distinct geographic areas — top geographies include Other, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06464926 about?
NCT06464926 is a clinical study titled "Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)". The purpose of this research study is to determine if the Enterra® Therapy System can decrease nausea and vomiting symptoms and improve the quality of life for patients with chronic nausea, with or without vomiting, that have normal gastric emptying.
What is the current status of trial NCT06464926?
This trial is currently recruiting. It is a NA study. The enrollment target is 148 participants. The study started on 2025-06-23. Estimated completion is 2030-06.
What conditions does trial NCT06464926 study?
This clinical trial studies the following conditions: Nausea, Vomiting. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06464926?
The interventions under investigation include: Enterra Therapy System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06464926?
This trial is sponsored by Enterra Medical, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06464926 being conducted?
This trial has 17 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.